Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study

被引：3
|
作者：
Ficorella, C
Morelli, MF
Ricevuto, E
Cannita, K
Porzio, G
Baldi, PL
Cianci, G
Di Rocco, ZC
Natoli, C
Tinari, N
De Galitiis, F
Calista, F
Marchetti, P
机构：
[1] Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy
[2] Univ Chieti, Dept Oncol & Neurosci, Sect Med Oncol, Chieti, Italy
来源：
BRITISH JOURNAL OF CANCER | 2004年 / 91卷 / 04期
关键词：
breast cancer; docetaxel; 5-fluorouracil;
D O I：
10.1038/sj.bjc.6601971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A dose-finding study was undertaken to determine the maximum-tolerated dose, and the recommended dose of docetaxel in combination with 12-h timed (22:00-10:00) flat infusion of 5-fluorouracil (5-FU) in metastatic breast cancer patients. This schedule seems to reduce the occurrence of stomatitis of the docetaxel and infusional 5-FU regimen.
引用
收藏
页码：618 / 620
页数：3
相关论文
共 50 条
  • [21] Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer
    O'Byrne, KJ
    Koukourakis, MI
    Saunders, MP
    Salisbury, AJ
    Isaacs, R
    Varcoe, S
    Taylor, M
    Ganesan, TS
    Harris, AL
    Talbot, DC
    BRITISH JOURNAL OF CANCER, 1998, 77 (11) : 1950 - 1956
  • [22] Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study
    Falcone, A
    Allegrini, G
    Lencioni, M
    Pfanner, E
    Brunetti, I
    Cianci, C
    Galli, C
    Masi, G
    Antonuzzo, A
    Conte, P
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (02) : 159 - 163
  • [23] Phase I Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Local or Metastatic Esophageal Cancer
    Iwasaki, Kenichi
    Osaka, Yoshiaki
    Tachibana, Shingo
    Suda, Takeshi
    Ota, Yoshihiro
    Hoshino, Sumito
    Tsuchida, Akihiko
    ANTICANCER RESEARCH, 2016, 36 (03) : 987 - 994
  • [24] Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer:: a preliminary phase II study
    Thuss-Patience, PC
    von Minckwitz, G
    Kretzschmar, A
    Loibl, S
    Schaller, G
    Dörken, B
    Reichardt, P
    ANTI-CANCER DRUGS, 2003, 14 (07) : 549 - 553
  • [25] CONTINUOUS-INFUSION OF 5-FLUOROURACIL IN METASTATIC COLORECTAL-CANCER PATIENTS
    DEGRAEFF, A
    VANDEWOUW, AJ
    VANDEVEN, PJG
    TJIA, PF
    WITTEVEEN, PO
    NEIJT, JP
    ZONNENBERG, BA
    VENDRIK, CPJ
    NORTIER, JWR
    BLIJHAM, GH
    CANCER JOURNAL - FRANCE, 1993, 6 (03): : 159 - 162
  • [26] Bolus 5-Fluorouracil as an Alternative Modality to Infusion 5-Fluorouracil in a Patient with Rectal Cancer and Capecitabine-induced Cardiotoxicity
    Shaib, Walid
    Lee, Veronica
    Saif, M. Wasif
    IN VIVO, 2009, 23 (05): : 821 - 826
  • [27] Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients:: A phase II study
    Nolè, F
    Munzone, E
    Mandalà, M
    Catania, C
    Orlando, L
    Zampino, MG
    Minchella, I
    Colleoni, M
    Peruzzotti, G
    Marrocco, E
    Goldhirsch, A
    ANNALS OF ONCOLOGY, 2001, 12 (01) : 95 - 100
  • [28] Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion
    Gebbia, V
    Mauceri, G
    Testa, A
    Tirrito, M
    Varvara, F
    Cucchiara, A
    Borsellino, N
    Girlando, A
    Ferrara, M
    Caruso, F
    ANTICANCER RESEARCH, 1999, 19 (3B) : 2289 - 2292
  • [29] Prospective randomized study of cyclophosphamide, epirubicin, and 5-fluorouracil versus cyclophosphamide, adriamycin, and 5-fluorouracil in advanced or recurrent breast cancer
    Kobayashi T.
    Koyama H.
    Oka T.
    Yasumura T.
    Kan N.
    Takatsuka Y.
    Noguchi M.
    Morimoto K.
    Suzuki T.
    Tobe T.
    Mori T.
    Breast Cancer, 1999, 6 (1) : 37 - 42
  • [30] Biweekly bolus 5-fluorouracil and leucovorin plus oxaliplatin in pretreated patients with advanced colorectal cancer: a dose-finding study
    Yang, TS
    Chen, JS
    Tang, R
    Chiang, JM
    Hsieh, PS
    Yeh, CY
    Changchien, CR
    ANTI-CANCER DRUGS, 2003, 14 (02) : 145 - 151
12345